Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield AZ hyaluronate knee Prior A…
    Ask Trek AI about this page
    Currentblue cross blue shield - arizonaPolicy N/A

    Preferred Drugs - Hyaluronate knee injection products

    Customize your policy alerts

    Sign up for all blue cross blue shield - arizona policy alerts

    Know when blue cross blue shield - arizona releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines preferred and non-preferred physician‑administered hyaluronate knee injection products for Health Choice Arizona and Health Choice Pathway and states that all listed products require prior authorization; applies to providers prescribing these intra‑articular knee injections.

    Policy Summary
    Payerblue cross blue shield - arizona
    PolicyPreferred Drugs - Hyaluronate knee injection products
    Policy CodePolicy N/A
    Change TypeAdministrative notice — preferred/non-preferred status
    Effective DateApr 1, 2021
    Next Review DateN/A
    Key ActionObtain prior authorization for all listed hyaluronate knee injection products; provide supporting documentation for non-preferred product requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    11

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    preferred HCPCS entries listed
    3non-preferred HCPCS entries listed
    4/1/2021effective date
    allprior auth required

    Coverage & Authorization

    General authorization requirement

    Coverage and authorization summary for listed hyaluronate knee injection products

    PA and product status: All listed hyaluronate injection products require prior authorization; preferred products are listed separately from non-preferred products.

    Effective 4/1/2021

    HCPCS Coding

    Preferred HCPCS CodesHCPCSCovered
    J7318Durolane
    J7321Hyalgan, Supartz FX, Visco-3
    J7322Hymovis
    J7323Euflexxa
    J7325Synvisc, Synvisc-One
    J7326Gel-One
    J7328Gelsyn-3
    J7329Trivisc
    J7331Synojoynt
    J7332Triluron
    Non-preferred HCPCS CodesHCPCSNot Covered
    J7320Genvisc 850
    J7324Orthovisc
    J7327Monovisc

    Provider Requirements & Prior Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for all listed hyaluronate knee injection products. Providers must obtain PA before administration or billing for these physician-administered drugs.

    • All products listed require prior authorization
    • Refer to Health Choice Prior Authorization (PA) Guidelines and PA Grids online
    Denial Risk

    Non-Preferred Product Requests

    A request for a non-preferred hyaluronate product requires supporting clinical documentation to justify medical necessity and why a preferred product is not appropriate.

    • Non-preferred products include: Genvisc 850 (J7320), Orthovisc (J7324), Monovisc (J7327)
    • Supporting documentation should substantiate the clinical rationale for using a non-preferred product
    Documentation Required

    Supporting Documentation and PA Guidance

    When requesting prior authorization for non-preferred products, include relevant clinical records, prior treatment history, and rationale for product selection. Follow the payer's PA submission instructions and use the available PA Grids.

    • Submit clinical records and prior treatment history
    • Use PA Grids and follow submission instructions found on the Health Choice provider websites
    Note

    PA Resources & Contacts

    For PA resources and submission details, visit the Health Choice provider sites or contact your Network Service Provider Performance Representative for questions.

    • HCA: https://www.healthchoiceaz.com/ -> Provider Tab -> PA Guidelines
    • HCP: https://www.healthchoicepathway.com/ -> Provider Tab -> Provider Information

    Background

    This notice identifies physician‑administered hyaluronate intra‑articular knee injection products that have been designated as preferred or non‑preferred for Health Choice Arizona and Health Choice Pathway, effective 4/1/2021. It is administrative guidance to providers about payer product status and authorization requirements rather than clinical treatment guidelines. (See listed preferred and non‑preferred HCPCS codes.)

    All products named in this notice require prior authorization. A request for a non‑preferred product will require supporting documentation to substantiate the medical necessity of using a non‑preferred product instead of a preferred alternative; providers should consult the payer’s Prior Authorization guidelines and PA grids for submission instructions and required documentation.

    Definitions

    Preferred product definition
    DefinitionPreferred: drug products designated by the payer as preferred for coverage under Health Choice Arizona (HCA) and Health Choice Pathway (HCP) effective 4/1/2021.
    ScopeApplies to Health Choice Arizona (HCA) and Health Choice Pathway (HCP).
    Effectivity dateEffective 4/1/2021.
    Covered HCPCS (examples)J7318 (Durolane); J7321 (Hyalgan, Supartz FX, Visco-3); J7322 (Hymovis); J7323 (Euflexxa); J7325 (Synvisc, Synvisc-One); J7326 (Gel-One); J7328 (Gelsyn-3); J7329 (Trivisc); J7331 (Synojoynt); J7332 (Triluron).
    Non-preferred product definition
    DefinitionNon-preferred: drug products designated by the payer as non-preferred; requests require supporting documentation to justify use.
    Policy Summary
    Payerblue cross blue shield - arizona
    PolicyPreferred Drugs - Hyaluronate knee injection products
    Policy CodePolicy N/A
    Change TypeAdministrative notice — preferred/non-preferred status
    Effective DateApr 1, 2021
    Next Review DateN/A
    Key ActionObtain prior authorization for all listed hyaluronate knee injection products; provide supporting documentation for non-preferred product requests.
    SourceLink
    On This Page
    Coverage & AuthorizationHCPCS CodingProvider Requirements & Prior AuthorizationBackgroundDefinitions
    ScopeApplies to Health Choice Arizona (HCA) and Health Choice Pathway (HCP).
    Effectivity dateEffective 4/1/2021.
    Non-preferred HCPCS (examples)J7320 (Genvisc 850); J7324 (Orthovisc); J7327 (Monovisc).
    Provider actionSupporting documentation and Health Choice Prior Authorization (PA) Guidelines/PA Grids must be followed when requesting non-preferred products; guidance available on payer websites.